Closing Stock Market SummaryThe stock market spent most of the session oscillating in a narrow range that included modest losses for the Dow, Nasdaq, and S&P 500. Investors were lacking conviction ahead of a slate of earnings news this week. Earnings results so far have been better than expected/feared, which helped limit selling interest, but valuation concerns kept the market from moving noticeably higher.
The market was able to log modest gains, though, thanks to a late afternoon rebound effort. The upside move coincided with a CNN reporter tweeting that House Speaker McCarthy said he thinks he has the 218 votes needed in the House to raise the debt ceiling. The sentiment shift may have been overdone, however, when considering that House Speaker McCarthy told CNBC earlier that a "no strings attached" debt ceiling increase will not pass the House. A proposal with strings attached (e.g., spending cuts in exchange for raising the debt ceiling) is unlikely to pass the Senate.
Still, the major indices all finished at their best levels of the day, leaving the S&P 500 just above 4,150. Even semiconductor equipment makers, which had been a notable pocket of weakness, came along for the afternoon rebound. The PHLX Semiconductor Index (SOX) was down as much as 1.5%, but closed with a modest 0.1% loss.
Weakness in the SOX was stemming from a Bloomberg report that Taiwan Semiconductor Manufacturing Co. (TSM 87.99, +0.79, +0.9%) may soon announce a cut in its FY23 capex budget to $28-32 billion from $32-36 billion.
Notably, Alphabet (GOOG 106.42, -3.04, -2.8%) still logged a sizable decline today despite the broader market improving before the close. This followed a New York Times piece that suggested Samsung is considering using Microsoft's (MSFT 288.80, +2.66, +0.9%) Bing as the default search engine on its devices as opposed to Google.
Most of the S&P 500 sectors were able to close with a gain led by real estate (+2.2%) and financials (+1.1%). Meanwhile, the energy (-1.3%) and communication services (-1.3%) sectors were the worst performers by a wide margin.
Separately, Treasuries settled with losses across the curve as the specter of the Fed raising rates again in May and then not pivoting to a rate-cut cycle anytime soon, along with a stronger-than-expected New York Empire State Manufacturing Survey for April, prompted some selling interest. The 2-yr note yield rose eight basis points to 4.18% and the 10-yr note yield rose seven basis points to 3.59%, unmoved in large part by the aforementioned tweet related to the debt ceiling conversation.
- Nasdaq Composite: +16.2% YTD
- S&P 500: +8.1% YTD
- Russell 2000: +3.2% YTD
- Dow Jones Industrial Average: +2.5% YTD
- S&P Midcap 400: +2.4% YTD
Reviewing today's economic data:
- April Empire State Manufacturing 10.8 (consensus -19.0); Prior -24.6
- April NAHB Housing Market Index 45 ( consensus 45); Prior 44
Looking ahead to Tuesday, market participants will receive the following economic data:
- 8:30 ET: March Housing Starts (consensus 1.458 mln; prior 1.450 mln) and Building Permits ( consensus 1.407 mln; prior 1.524 mln)


Research Calls
- Upgrades:
- Biogen (BIIB) upgraded to Overweight from Neutral at Piper Sandler; tgt raised to $346
- Dexcom (DXCM) upgraded to Strong Buy from Outperform at Raymond James; tgt raised to $138
- HP Inc. (HPQ) upgraded to Overweight from Neutral at JP Morgan; tgt raised to $35
- Lumentum (LITE) upgraded to Overweight from Neutral at JP Morgan; tgt raised to $60
- Ollie's Bargain Outlet (OLLI) upgraded to Neutral from Underweight at JP Morgan; tgt raised to $66
- Sallie Mae (SLM) upgraded to Overweight from Neutral at JP Morgan; tgt raised to $17
- Taiwan Semiconductor Manufacturing (TSM) upgraded to Positive from Neutral at Susquehanna; tgt $126
- Downgrades:
- AES (AES) downgraded to Peer Perform from Outperform at Wolfe Research
- AngioDynamics (ANGO) downgraded to Outperform from Strong Buy at Raymond James; tgt lowered to $13
- Catalent (CTLT) downgraded to Neutral from Outperform at Robert W. Baird; tgt lowered to $53
- Commscope (COMM) downgraded to Hold from Buy at Jefferies; tgt lowered to $5.50
- ConocoPhillips (COP) downgraded to Neutral from Buy at Mizuho; tgt lowered to $128
- Dell (DELL) downgraded to Neutral from Overweight at JP Morgan; tgt $47
- Essex Property (ESS) downgraded to Underperform from Market Perform at BMO Capital Markets; tgt lowered to $200
- Infosys (INFY) downgraded to Neutral from Outperform at Macquarie
- Kaltura (KLTR) downgraded to Underperform from Neutral at BofA Securities; tgt lowered to $1.75
- Meta Platforms (META) downgraded to Neutral from Buy at New Street; tgt $220
- Ovintiv (OVV) downgraded to Equal Weight from Overweight at Wells Fargo; tgt lowered to $40
- PENN Entertainment (PENN) downgraded to Mkt Perform from Mkt Outperform at JMP Securities
- Teradyne (TER) downgraded to Underweight from Neutral at JP Morgan; tgt lowered to $81
- Texas Roadhouse (TXRH) downgraded to Mkt Perform from Outperform at Raymond James
- ViewRay (VRAY) downgraded to Hold from Buy at Jefferies; tgt lowered to $1.25
- Wolfspeed (WOLF) downgraded to Neutral from Overweight and placed on Negative Catalyst Watch at JP Morgan; tgt lowered to $65
- Others:
- Autodesk (ADSK) initiated with an Outperform at William Blair
- Check Point Software (CHKP) initiated with an Outperform at Wolfe Research; tgt $151
- Corsair Gaming (CRSR) initiated with a Neutral at Goldman; tgt $20
- Fluence (FLNC) initiated with a Market Perform at BMO Capital Markets; tgt $24
- Hilton Grand Vacations (HGV) initiated with a Neutral at BofA Securities; tgt $50
- Rallybio (RLYB) initiated with a Buy at H.C. Wainwright; tgt $18
- Replimune (REPL) assumed with an Overweight at Piper Sandler; tgt $44
- STAAR Surgical (STAA) initiated with a Neutral at Piper Sandler; tgt $65
- Stem (STEM) initiated with a Market Perform at BMO Capital Markets; tgt $3.50
- Travel + Leisure Co (TNL) initiated with an Underperform at BofA Securities; tgt $42
- Viridian Therapeutics (VRDN) initiated with an Overweight at Wells Fargo; tgt $46
Gapping down
News:
- HIVE -3.7% (reports March production)
- ASIX -2% (Chair of the Board Michael Marberry to retire effective June 15; Todd Karran named as new Chair)
- GALT -2% (files mixed securities shelf offering)
- RCEL -1% (files for $200 mln mixed securities shelf offering)
- VNT -0.9% (announced the sale of its Global Traffic Technologies business to Miovision for $107 mln)
Analyst comments:
- COMM -2.8% (downgraded to Hold from Buy at Jefferies)
- AES -1.5% (downgraded to Peer Perform from Outperform at Wolfe Research)
- ANGO -1.4% (downgraded to Outperform from Strong Buy at Raymond James)
- ESS -1.2% (downgraded to Underperform from Market Perform at BMO Capital Markets)
Gapping up
In reaction to earnings/guidance:
- AMRX +8.8% (Q1 guidance), AQN +7.2% (Algonquin Power & Utilities and American Electric Power (AEP) terminate Kentucky power transaction; AQN reaffirms guidance), MTB +3.4%, LIVN +3.3% (CEO Damien McDonald resigns; co also guides Q1 revs above consensus), GTX +2.3%, .
Other news:
- RXDX +69.7% (to be acquired by Merck (MRK) for $200.00 per share)
- PCVX +9.8% (Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24)
- AGEN +4.8% (receives Fast Track Designation for Botensilimab and Balstilimab in colorectal cancer)
- CLLS +3.4% (Presents Preclinical Data on TALEN-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting)
- MAXR +2.7% (receives majority of regulatory consents required for previously proposed acquisition by Advent International)
- OCUL +2.1% (to Present Pre-Clinical and Clinical Data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting)
- PEBO +2% (receives all necessary regulatory approvals for the merger between Peoples and Limestone Bancorp (LMST) )
- AMX +2% (approved buyback program fund for the April 2023 -- April 2024 period of MXP$20,000,000,000)
- ME +1.8% (Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1)
- YY +1.7% (announces repurchase right notification for 0.750% convertible senior notes due 2025)
- SGML +1.5% (initiates production of green lithium)
- ARGX +1.4% (Argenx and Genmab (GMAB) enter partnership to advance antibody therapies in immunology and oncology)
Analyst comments:
- DXCM +2% (upgraded to Strong Buy from Outperform at Raymond James)
- BIIB +1.3% (upgraded to Overweight from Neutral at Piper Sandler)